Molecular mechanisms of cisplatin resistance in bladder cancer.
about
Heterogeneous nuclear ribonucleoprotein K is associated with poor prognosis and regulates proliferation and apoptosis in bladder cancer.Transcriptome profiling of a multiple recurrent muscle-invasive urothelial carcinoma of the bladder by deep sequencing.Novel molecular targets for urothelial carcinomamiR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.Nanoparticle modulation of the tumor microenvironment enhances therapeutic efficacy of cisplatin.Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches.ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.SOX17 increases the cisplatin sensitivity of an endometrial cancer cell lineAn Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder CancerCollecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation.Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy.Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.SOX17 is a tumor suppressor in endometrial cancerGenomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell LinesmTOR inhibitors in urinary bladder cancer.Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines.Potential therapeutic roles of tanshinone IIA in human bladder cancer cellsDual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancerProteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways.Understanding the Role of Non-Coding RNAs in Bladder Cancer: From Dark Matter to Valuable Therapeutic Targets.Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer.Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis.Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.Targeting DNA Methyltranferases in Urological Tumors.
P2860
Q33844635-A144B886-6F64-471E-86B2-BE12BB39AB5BQ35119047-29855EDB-40BF-48CE-8560-60C226476C00Q35527068-53CAD697-0200-4E8E-A2E5-6474B1732CDAQ35557027-E5AD0853-D745-41DB-BF05-9766FDE7F54AQ36217643-F3D4BDCB-0B5C-4B84-9FBB-639582FAA4CCQ36589753-9F43516F-B185-4A06-A672-79F43415C2FEQ36739002-5720E157-3EF4-4C72-9C4C-BEDD8EA889A6Q36783398-4709000E-D55C-468E-8025-CE51292B0D6AQ37290684-D53075C7-6F78-415C-A478-7442E85D4AE8Q37327370-506B6423-7AC2-4F0E-AB25-F9C93AA23556Q37531501-110FA6BD-1806-4380-ACF6-5CE64BD05971Q37682756-B715D1C9-023C-437F-872C-ABA77856B94AQ37689061-3B9625AD-917A-43E8-B77D-F5DF544FE6A9Q37718224-257EA11D-1F8C-40F1-A694-CB28B1626A51Q37737877-48990E45-D861-436F-8E96-E6F4F81500E4Q38647100-5DCAAB15-985B-44FB-97B1-59288AC28B88Q38737064-236A089C-9225-4D96-A394-BBC079F9C5D4Q38816754-DB6FB1A1-8399-4733-B019-59A9DD10C4F0Q38959528-348107FE-5E7F-4081-8457-D118212D0ECCQ39005742-15995FCE-BA7A-448A-B910-8BCCA5425CDBQ39069268-64E3045D-0B90-4157-9456-2C7FD87D9E4DQ39432577-BEAF816A-D05F-492C-ACEB-2676D753E9A9Q39540757-21DE64F9-EF46-4B3A-B4D7-4115749026B3Q47291991-DB88FB1D-0949-4FC4-90E0-F8DF36CD284BQ49168184-C2CEEE83-BB17-4E05-95C0-4AEC5E6012FEQ49805034-B828594E-5A7C-4850-BC5C-5F4288B8692BQ55435258-B7AA8A2B-CD3C-4719-BA2F-3A00CCF990BC
P2860
Molecular mechanisms of cisplatin resistance in bladder cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Molecular mechanisms of cisplatin resistance in bladder cancer.
@en
Molecular mechanisms of cisplatin resistance in bladder cancer.
@nl
type
label
Molecular mechanisms of cisplatin resistance in bladder cancer.
@en
Molecular mechanisms of cisplatin resistance in bladder cancer.
@nl
prefLabel
Molecular mechanisms of cisplatin resistance in bladder cancer.
@en
Molecular mechanisms of cisplatin resistance in bladder cancer.
@nl
P2860
P356
P1476
Molecular mechanisms of cisplatin resistance in bladder cancer
@en
P2093
Ross M Drayton
P2860
P304
P356
10.1586/ERA.11.201
P50
P577
2012-02-01T00:00:00Z